Find comprehensive information on Carcinoma Endometrium (C), also known as Endometrial Cancer or Uterine Cancer. This resource offers guidance on diagnosis, ICD-10 coding, clinical documentation best practices, and healthcare management of endometrial carcinoma for medical professionals. Learn about staging, treatment options, and relevant medical terminology associated with uterine cancer.
Also known as
Malignant neoplasm of corpus uteri
Cancer specifically affecting the body of the uterus (endometrium).
Overlapping lesion of corpus uteri
Cancer involving the body of the uterus and overlapping nearby areas.
Malignant neoplasm of cervix uteri
Cancer affecting the cervix, the lower part of the uterus connecting to the vagina.
Secondary malignant neoplasm of other specified sites
Cancers that have spread (metastasized) to the uterus from another primary site.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the endometrial carcinoma specified as in situ?
When to use each related code
| Description |
|---|
| Cancer of the uterine lining. |
| Precancerous changes in the uterine lining. |
| Benign smooth muscle tumors of the uterus. |
Failing to document laterality (right, left, bilateral, etc.) if applicable can lead to inaccurate coding and reimbursement issues.
Insufficient documentation of histology type (e.g., adenocarcinoma, clear cell) may result in coding errors and affect treatment planning.
Discrepancies between documented stage and grade of the carcinoma can impact accurate coding, treatment, and prognosis reporting.
Q: What are the most effective current treatment strategies for managing advanced or recurrent endometrial carcinoma in a patient with comorbidities?
A: Managing advanced or recurrent endometrial carcinoma with comorbidities requires a personalized approach balancing treatment efficacy with patient safety. Current guidelines from organizations like the NCCN recommend considering factors such as patient performance status, histological subtype (e.g., endometrioid, serous), molecular profile (e.g., POLE mutation, microsatellite instability), and specific comorbidities when making treatment decisions. Options include systemic therapy with chemotherapy (e.g., carboplatin/paclitaxel, doxorubicin/cisplatin), targeted therapies (e.g., lenvatinib, pembrolizumab), hormonal therapy (e.g., megestrol acetate, letrozole), or a combination thereof. For example, patients with endometrioid histology and microsatellite instability may benefit from immunotherapy, while those with POLE mutations may have a better prognosis and could be candidates for less aggressive approaches. Palliative care and symptom management are also crucial for improving quality of life. Explore how molecular profiling can guide treatment decisions for advanced endometrial carcinoma and consider implementing a multidisciplinary approach involving medical oncology, gynecologic oncology, and palliative care for optimal patient outcomes. Learn more about the latest clinical trial data impacting treatment selection for this complex patient population.
Q: How can clinicians differentiate between type 1 and type 2 endometrial carcinoma during the diagnostic workup, and what are the key implications for prognosis and treatment?
A: Differentiating between type 1 and type 2 endometrial carcinoma is critical for prognosis and treatment planning. Type 1, typically endometrioid adenocarcinoma, is often associated with estrogen excess, obesity, and a relatively favorable prognosis. Histologically, it often exhibits glandular formations. Type 2, including serous and clear cell carcinomas, is less common, not linked to estrogen, and carries a poorer prognosis. These often show a more solid growth pattern with significant nuclear atypia. Diagnostic workup should include a thorough endometrial biopsy for histopathological evaluation. Immunohistochemistry can further clarify the subtype, especially in challenging cases. For instance, p53 expression is often aberrant in type 2 tumors. Distinguishing between these types informs treatment decisions. Type 1 often responds well to progestin therapy in early stages, while type 2 carcinomas require more aggressive interventions like surgery, chemotherapy, and potentially targeted therapies. Consider implementing a standardized pathology review process for all endometrial carcinoma diagnoses to ensure accurate subtyping and explore how immunohistochemical markers can refine diagnostic accuracy and inform personalized treatment strategies. Learn more about the role of molecular profiling in further stratifying risk within these subtypes.
Patient presents with complaints consistent with possible endometrial carcinoma. Symptoms include abnormal uterine bleeding, postmenopausal bleeding, pelvic pain, and abnormal vaginal discharge. Patient reports [duration of symptoms]. Relevant medical history includes [list relevant medical history, e.g., nulliparity, obesity, history of tamoxifen use, family history of Lynch syndrome, polycystic ovary syndrome]. Physical examination revealed [findings, e.g., enlarged uterus, palpable adnexal mass]. Differential diagnosis includes endometrial hyperplasia, uterine fibroids, endometrial polyps, and other gynecologic malignancies. To evaluate for uterine cancer, a transvaginal ultrasound was performed, revealing [ultrasound findings, e.g., thickened endometrial stripe]. An endometrial biopsy was performed and sent for histopathologic evaluation. Preliminary pathology report indicates [preliminary findings]. Given the patient's presentation and preliminary findings, a diagnosis of endometrial carcinoma is suspected. Further workup, including imaging studies such as CT scan of the abdomen and pelvis and chest x-ray, will be performed to assess for metastatic disease. A consultation with gynecologic oncology has been scheduled to discuss treatment options, including surgery (hysterectomy, bilateral salpingo-oophorectomy), radiation therapy, chemotherapy, and hormonal therapy. The patient's prognosis will depend on the final histologic grade, stage, and myometrial invasion of the tumor. This documentation will be updated following the final pathology report and consultation with gynecologic oncology. ICD-10 code C54.9 (Malignant neoplasm of endometrium, unspecified) is provisionally assigned, pending definitive diagnosis. Medical billing codes will be updated based on procedures performed and treatment plan.